1. Home
  2. REBN vs PHIO Comparison

REBN vs PHIO Comparison

Compare REBN & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reborn Coffee Inc.

REBN

Reborn Coffee Inc.

HOLD

Current Price

$1.26

Market Cap

11.5M

ML Signal

HOLD

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$1.12

Market Cap

11.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REBN
PHIO
Founded
2015
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.5M
11.2M
IPO Year
2017
2011

Fundamental Metrics

Financial Performance
Metric
REBN
PHIO
Price
$1.26
$1.12
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$14.00
AVG Volume (30 Days)
51.2K
146.6K
Earning Date
04-22-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,094,628.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
36.54
N/A
52 Week Low
$0.91
$0.81
52 Week High
$2.95
$4.19

Technical Indicators

Market Signals
Indicator
REBN
PHIO
Relative Strength Index (RSI) 47.39 53.92
Support Level $1.20 $0.99
Resistance Level $2.02 $1.14
Average True Range (ATR) 0.12 0.06
MACD -0.00 0.00
Stochastic Oscillator 31.71 50.00

Price Performance

Historical Comparison
REBN
PHIO

About REBN Reborn Coffee Inc.

Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is a company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in two reportable segments: Reborn Coffee, which includes both the wholesale and retail sales of coffee, water, and other beverages, and Reborn Logistics, which provides freight forwarding services.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: